An FDA advisory panel voted 11-3 late Monday to recommend that the regulatory agency approve the nonprescription form of orlistat, which Glaxo would market as Alli (pronounced "ally"). The agency is not bound by the recommendation but usually follows the advice of its expert panels.Less good news. You have to take your underpants off in the dark.
"We are excited about the potential opportunity to provide consumers with an FDA-approved over-the-counter option that promotes gradual yet meaningful weight loss," Quesnelle said.
When taken with meals, orlistat blocks the absorption of about one-quarter of any fat consumed.
A bevy of potentially distasteful and embarrassing side effects struck about half the participants in trials of the drug. Those side effects, including fecal incontinence, gas and oily discharge that spotted the undergarments of trial participants, are likely to limit the appeal of the pill.